107 related articles for article (PubMed ID: 22932315)
1. An investigation into the structure-activity relationships associated with the systematic modification of the β(2)-adrenoceptor agonist indacaterol.
Beattie D; Beer D; Bradley ME; Bruce I; Charlton SJ; Cuenoud BM; Fairhurst RA; Farr D; Fozard JR; Janus D; Rosethorne EM; Sandham DA; Sykes DA; Trifilieff A; Turner KL; Wissler E
Bioorg Med Chem Lett; 2012 Oct; 22(19):6280-5. PubMed ID: 22932315
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action.
Battram C; Charlton SJ; Cuenoud B; Dowling MR; Fairhurst RA; Farr D; Fozard JR; Leighton-Davies JR; Lewis CA; McEvoy L; Turner RJ; Trifilieff A
J Pharmacol Exp Ther; 2006 May; 317(2):762-70. PubMed ID: 16434564
[TBL] [Abstract][Full Text] [Related]
3. The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist.
Arnold N; Beattie D; Bradley M; Brearley A; Brown L; Charlton SJ; Fairhurst RA; Farr D; Fozard J; Fullerton J; Gosling M; Hatto J; Janus D; Jones D; Jordan L; Lewis C; Maas J; McCarthy C; Mercer M; Oakman H; Press N; Profit R; Schuerch F; Sykes D; Taylor RJ; Trifilieff A; Tuffnell A
Bioorg Med Chem Lett; 2014 Sep; 24(17):4341-7. PubMed ID: 25065493
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterization of abediterol, a novel inhaled β(2)-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models.
Aparici M; Gómez-Angelats M; Vilella D; Otal R; Carcasona C; Viñals M; Ramos I; Gavaldà A; De Alba J; Gras J; Cortijo J; Morcillo E; Puig C; Ryder H; Beleta J; Miralpeix M
J Pharmacol Exp Ther; 2012 Aug; 342(2):497-509. PubMed ID: 22588259
[TBL] [Abstract][Full Text] [Related]
5. Discovery of TD-4306, a long-acting β2-agonist for the treatment of asthma and COPD.
McKinnell RM; Klein U; Linsell MS; Moran EJ; Nodwell MB; Pfeiffer JW; Thomas GR; Yu C; Jacobsen JR
Bioorg Med Chem Lett; 2014 Jul; 24(13):2871-6. PubMed ID: 24835980
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo preclinical profile of abediterol (LAS100977), an inhaled long-acting β2-adrenoceptor agonist, compared with indacaterol, olodaterol and vilanterol.
Aparici M; Gavaldà A; Ramos I; Carcasona C; Otal R; Fernández-Blanco JA; Montero JL; García VM; López R; De Alba J; Doe C; Puig C; Vilella D; Miralpeix M
Eur J Pharmacol; 2016 Jan; 770():61-9. PubMed ID: 26656755
[TBL] [Abstract][Full Text] [Related]
7. The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.
Baur F; Beattie D; Beer D; Bentley D; Bradley M; Bruce I; Charlton SJ; Cuenoud B; Ernst R; Fairhurst RA; Faller B; Farr D; Keller T; Fozard JR; Fullerton J; Garman S; Hatto J; Hayden C; He H; Howes C; Janus D; Jiang Z; Lewis C; Loeuillet-Ritzler F; Moser H; Reilly J; Steward A; Sykes D; Tedaldi L; Trifilieff A; Tweed M; Watson S; Wissler E; Wyss D
J Med Chem; 2010 May; 53(9):3675-84. PubMed ID: 20402514
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the Indacaterol-Regulated Transcriptome in Human Airway Epithelial Cells Implicates Gene Expression Changes in the Adverse and Therapeutic Effects of
Yan D; Hamed O; Joshi T; Mostafa MM; Jamieson KC; Joshi R; Newton R; Giembycz MA
J Pharmacol Exp Ther; 2018 Jul; 366(1):220-236. PubMed ID: 29653961
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and evaluation of dual pharmacology β2-adrenoceptor agonists and PDE4 inhibitors.
Huang L; Shan W; Zhou Q; Xie J; Lai K; Li X
Bioorg Med Chem Lett; 2014 Jan; 24(1):249-53. PubMed ID: 24300734
[TBL] [Abstract][Full Text] [Related]
10. Effects of chronic treatment with the new ultra-long-acting β2 -adrenoceptor agonist indacaterol alone or in combination with the β1 -adrenoceptor blocker metoprolol on cardiac remodelling.
Rinaldi B; Donniacuo M; Sodano L; Gritti G; Martuscelli E; Orlandi A; Rafaniello C; Rossi F; Calzetta L; Capuano A; Matera MG
Br J Pharmacol; 2015 Jul; 172(14):3627-37. PubMed ID: 25825265
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacological and clinical profile of indacaterol maleate (Onbrez®), an inhaled long-acting β₂-adrenoceptor agonist].
Suzuki K; Uchiyama M; Matsushima S; Yoshiki M; Kitawaki T
Nihon Yakurigaku Zasshi; 2012 Jul; 140(1):36-43. PubMed ID: 22790232
[No Abstract] [Full Text] [Related]
12. The long-acting β2 -adrenoceptor agonist, indacaterol, enhances glucocorticoid receptor-mediated transcription in human airway epithelial cells in a gene- and agonist-dependent manner.
Joshi T; Johnson M; Newton R; Giembycz MA
Br J Pharmacol; 2015 May; 172(10):2634-53. PubMed ID: 25598440
[TBL] [Abstract][Full Text] [Related]
13. GS-5759, a Bifunctional β2-Adrenoceptor Agonist and Phosphodiesterase 4 Inhibitor for Chronic Obstructive Pulmonary Disease with a Unique Mode of Action: Effects on Gene Expression in Human Airway Epithelial Cells.
Joshi T; Yan D; Hamed O; Tannheimer SL; Phillips GB; Wright CD; Kim M; Salmon M; Newton R; Giembycz MA
J Pharmacol Exp Ther; 2017 Feb; 360(2):324-340. PubMed ID: 27927912
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic characterization of indacaterol, a novel beta 2-adrenoceptor agonist.
Sayers I; Hawley J; Stewart CE; Billington CK; Henry A; Leighton-Davies JR; Charlton SJ; Hall IP
Br J Pharmacol; 2009 Sep; 158(1):277-86. PubMed ID: 19422388
[TBL] [Abstract][Full Text] [Related]
15. Indacaterol inhibits tumor cell invasiveness and MMP-9 expression by suppressing IKK/NF-κB activation.
Lee SU; Ahn KS; Sung MH; Park JW; Ryu HW; Lee HJ; Hong ST; Oh SR
Mol Cells; 2014 Aug; 37(8):585-91. PubMed ID: 25134539
[TBL] [Abstract][Full Text] [Related]
16. Discovery of muscarinic acetylcholine receptor antagonist and beta 2 adrenoceptor agonist (MABA) dual pharmacology molecules.
Hughes AD; Chin KH; Dunham SL; Jasper JR; King KE; Lee TW; Mammen M; Martin J; Steinfeld T
Bioorg Med Chem Lett; 2011 Mar; 21(5):1354-8. PubMed ID: 21310610
[TBL] [Abstract][Full Text] [Related]
17. Metabolism and pharmacokinetics of indacaterol in humans.
Kagan M; Dain J; Peng L; Reynolds C
Drug Metab Dispos; 2012 Sep; 40(9):1712-22. PubMed ID: 22648561
[TBL] [Abstract][Full Text] [Related]
18. The in vitro pharmacology of GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long acting β2-adrenoceptor agonist.
Tannheimer SL; Sorensen EA; Cui ZH; Kim M; Patel L; Baker WR; Phillips GB; Wright CD; Salmon M
J Pharmacol Exp Ther; 2014 Apr; 349(1):85-93. PubMed ID: 24513870
[TBL] [Abstract][Full Text] [Related]
19. Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties?
Lombardi D; Cuenoud B; Krämer SD
Eur J Pharm Sci; 2009 Dec; 38(5):533-47. PubMed ID: 19819331
[TBL] [Abstract][Full Text] [Related]
20. Profiling the bronchodilator effects of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease.
Vogelmeier C; Magnussen H; LaForce C; Owen R; Kramer B
Ther Adv Respir Dis; 2011 Oct; 5(5):345-57. PubMed ID: 21719531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
